Peer-reviewed Articles on Cannabinoids and Cancer

Peer Reviewed Cannabis and Cancer References (download PDF)

  1. Argaw, A. et al. Concerted Action of CB1 Cannabinoid Receptor and Deleted in Colorectal Cancer in Axon Guidance. J Neurosci 31, 1489-1499 (2011).
  2. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets (2011).
  3. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. Cell Death Differ (2011).
  4. Karasu, T., Marczylo, T. H., Maccarrone, M. & Konje, J. C. The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility. Hum Reprod Update (2011).
  5. Torres, S. et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Mol Cancer Ther 10, 90-103 (2011).
  6. Hsu, E. S. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther 17, 476-486 (2010).
  7. Van Ryckeghem, F. & Van Belle, S. Management of chemotherapy-induced nausea and vomiting. Acta Clin Belg 65, 305-310 (2010).
  8. Jordan, K. et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer (2010).
  9. Liu, W. M., Fowler, D. W. & Dalgleish, A. G. Cannabis-Derived Substances in Cancer Therapy - an Emerging Anti-Inflammatory Role for the Cannabinoids. Curr Clin Pharmacol (2010).
  10. Larrinaga, G. et al. Cannabinoid CB1 Receptor Is Down-regulated in Clear Cell Renal Cell Carcinoma. J Histochem Cytochem (2010).
  11. Lam, P. M., Marczylo, T. H. & Konje, J. C. Simultaneous measurement of three N- acylethanolamides in human bio-matrices using ultra performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2010).
  12. Tazi, E. & Errihani, H. Treatment of cachexia in oncology. Indian J Palliat Care 16, 129-137 (2010).
  13. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol (2010).
  14. Amoako, A. A. et al. Quantitative analysis of anandamide and related acylethanolamides in human seminal plasma by ultra performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2010).
  15. Peat, S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs 16, 481- 485 (2010).
  16. Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene (2010).
  17. Preet, A. et al. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Prev Res (Phila) (2010).
  18. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids Attenuate Cancer Pain and Proliferation in a Mouse Model. Neurosci Lett (2010).
  19. Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S. & Huestis, M. A. Plasma Cannabinoid Pharmacokinetics following Controlled Oral {Delta}9- Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. Clin Chem (2010).
  20. Lin, H. C. et al. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol (2010).
  21. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 70, 656-663 (2010).
  22. Lee, T. Y., Lee, K. C. & Chang, H. H. Modulation of the cannabinoid receptors by andrographolide attenuates hepatic apoptosis following bile duct ligation in rats with fibrosis. Apoptosis (2010).
  23. Yang, Q., Liu, H. Y., Zhang, Y. W., Wu, W. J. & Tang, W. X. Anandamide induces cell death through lipid rafts in hepatic stellate cells. J Gastroenterol Hepatol (2010).
  24. Labar, G., Wouters, J. & Lambert, D. M. A Review on the Monoacylglycerol Lipase: At the Interface between Fat and Endocannabinoid Signalling. Curr Med Chem (2010).
  25. Frampton, G., Coufal, M., Li, H., Ramirez, J. & Demorrow, S. Opposing actions of endocannabinoids on cholangiocarcinoma growth is via the differential activation of Notch signaling. Exp Cell Res (2010).
  26. Xian, X. S. et al. Effect of a synthetic cannabinoid agonist on the proliferation and invasion of gastric cancer cells. J Cell Biochem (2010).
  27. Jesus, M. L. et al. Opposite changes in cannabinoid CB(1) and CB(2) receptor expression in human gliomas. Neurochem Int (2010).
  28. Laezza, C. et al. Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell. Endocr Relat Cancer (2010).
  29. Wu, W. J. et al. [Membrane cholesterol mediates the endocannabinoids-anandamide effection on HepG2 cells.]. Zhonghua Gan Zang Bing Za Zhi 18, 204-208 (2010).
  30. Fonseca, B. M. et al. N-Acylethanolamine Levels and Expression of Their Metabolizing Enzymes during Pregnancy. Endocrinology (2010).
  31. Fernandez-Solari, J., Prestifilippo, J. P., Ossola, C. A., Rettori, V. & Elverdin, J. C. Participation of the endocannabinoid system in lipopolysaccharide-induced inhibition of salivary secretion. Arch Oral Biol (2010).
  32. Whyte, D. A. et al. Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells. Pharmacology 85, 328-335 (2010).
  33. Soneji, N. D., Paule, C. C., Mlynarczyk, M. & Nagy, I. Effects of cannabinoids on capsaicin receptor activity following exposure of primary sensory neurons to inflammatory mediators. Life Sci (2010).
  34. Reiss, C. S. Cannabinoids and Viral Infections. Pharmaceuticals (Basel) 3, 1873- 1886 (2010).
  35. Santha, P., Jenes, A., Somogyi, C. & Nagy, I. The endogenous cannabinoid anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated currents in rat cultured primary sensory neurons. Acta Physiol Hung 97, 149-158 (2010).
  36. Ford, L. A. et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160, 762-771 (2010).
  37. Brown, I. et al. Cannabinoid receptor dependent and independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor positive and negative prostate cancer cell lines. Carcinogenesis (2010).
  38. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 9, 196 (2010).
  39. Park, J. Y. et al. Alcohol intake and risk of colorectal cancer: Results from the UK Dietary Cohort Consortium. Br J Cancer (2010).
  40. Linsalata, M. et al. Effects of anandamide on polyamine levels and cell growth in human colon cancer cells. Anticancer Res 30, 2583-2589 (2010).
  41. Marcu, J. P. et al. Cannabidiol Enhances the Inhibitory Effects of {Delta}9- Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. Mol Cancer Ther (2010).
  42. Petrosino, S. & Di Marzo, V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11, 51-62 (2010).
  43. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2) Receptors in Health and Disease. Curr Med Chem (2010).
  44. Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential Regulation of Behavioral Tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology (2010).
  45. Gao, M., Wang, M., Miller, K. D., Hutchins, G. D. & Zheng, Q. H. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorg Med Chem (2010).
  46. Zoppi, S. et al. Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced Excitotoxicity and Neuroinflammation. Neuropsychopharmacology (2010).
  47. Cui, J. H. et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett (2010).
  48. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double transgenic mice. Brain Res (2010).
  49. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol (2010).
  50. Miro, A. M. et al. 17beta-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol (2010).
  51. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B. Anti-proliferative Effect of a Putative Endocannabinoid; 2-Arachidonylglyceryl Ether in Prostate Carcinoma Cells. Prostaglandins Other Lipid Mediat (2010).
  52. Nunez, M., Perdomo, S., Moreta, J., Santos-Briz, A. & Gonzalez-Sarmiento, R. The G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients. Clin Transl Oncol 12, 825-828 (2010).
  53. Ward, H., Luben, R. N., Wareham, N. J. & Khaw, K. T. CHD risk in relation to alcohol intake from categorical and open-ended dietary instruments. Public Health Nutr 1-8 (2010).
  54. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 53, 298-306 (2010).
  55. Miranville, A., Herling, A. W., Biemer-Daub, G. & Voss, M. D. Reversal of Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct Effect of CB1 Antagonism on Adipose Tissue Macrophages. Obesity (Silver Spring) (2010).
  56. Kawamata, T., Niiyama, Y., Yamamoto, J. & Furuse, S. Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition. J Anesth (2010).
  57. Fowler, C. J. et al. Targeting the Endocannabinoid System for the Treatment of Cancer - A Practical View. Curr Top Med Chem (2010).
  58. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol (2010).
  59. Gallotta, D. et al. Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways. Biochem Pharmacol (2010).
  60. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-{gamma}. J Biol Chem (2010).
  61. De Laurentiis, A., Fernandez Solari, J., Mohn, C., Zorrilla Zubilete, M. & Rettori, V. Endocannabinoid System Participates in Neuroendocrine Control of Homeostasis. Neuroimmunomodulation 17, 153-156 (2010).
  62. Thors, L. et al. Fatty Acid Amide Hydrolase in Prostate Cancer: Association with Disease Severity and Outcome, CB(1) Receptor Expression and Regulation by IL-4. PLoS One 5, (2010).
  63. Phillips, R. S. et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 9, CD007786 (2010).
  64. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. The cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3 cells. J Immunotoxicol (2009).
  65. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Non- psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009).
  66. Wainwright, C. & McGrath, J. Editorial. Br J Pharmacol 158, 393-394 (2009).
  67. Guindon, J. & Hohmann, A. G. The Endocannabinoid System and Pain. CNS
  68. Neurol Disord Drug Targets (2009).
  69. Horn, C. C., Still, L., Fitzgerald, C. & Friedman, M. I. Food restriction, refeeding, and gastric fill fail to affect emesis in musk shrews. Am J Physiol Gastrointest Liver Physiol (2009).
  70. Freimuth, N., Ramer, R. & Hinz, B. Antitumorigenic effects of cannabinoids beyond apoptosis. J Pharmacol Exp Ther (2009).
  71. Tournier, N. et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 1-11 (2009).
  72. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-Related Pain. J Pain Symptom Manage (2009).
  73. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther (2009).
  74. Rask-Andersen, M., Olszewski, P. K., Levine, A. S. & Schioth, H. B. Molecular mechanisms underlying anorexia nervosa: Focus on human gene association studies and systems controlling food intake. Brain Res Rev (2009).
  75. De Filippis, D. et al. LEVELS OF ENDOCANNABINOIDs AND PALMITOYLETHANOLAMIDE AND THEIR PHARMACOLOGICAL MANIPULATION IN CHRONIC GRANULOMATOUS INFLAMMATION IN RATs. Pharmacol Res (2009).
  76. Leelawat, S., Leelawat, K., Narong, S. & Matangkasombut, O. The Dual Effects of Delta(9)-Tetrahydrocannabinol on Cholangiocarcinoma Cells: Anti-Invasion Activity at Low Concentration and Apoptosis Induction at High Concentration. Cancer Invest (2009).
  77. Ramer, R., Merkord, J., Rohde, H. & Hinz, B. Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1. Biochem Pharmacol (2009).
  78. Brighton, P. J. et al. Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells. Mol Endocrinol (2009).
  79. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids, their congeners and COX-2 metabolites. J Chromatogr B Analyt Technol Biomed Life Sci (2009).
  80. Takeda, S., Yamamoto, I. & Watanabe, K. Modulation of Delta(9)- tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology 259, 25-32 (2009).
  81. Cotter, J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. Oncol Nurs Forum 36, 345-352 (2009).
  82. Wegener, N. & Koch, M. Neurobiology and Systems Physiology of the Endocannabinoid System. Pharmacopsychiatry 42, S79-S86 (2009)
  83. Brizzi, A. et al. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. J Med Chem (2009).
  84. Izzo, A. A. & Camilleri, M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res (2009).
  85. Yin, H. et al. Lipid G-protein-coupled Receptor Ligand Identification Using beta - arrestin Pathhunter Assay. J Biol Chem (2009).
  86. Villanueva, A. et al. Central Cannabinoid-1 Receptor Antagonist Administration Prevents Endotoxic Hypotension Affecting Norepinephrine Release in the Preoptic Anterior Hypothalamic Area. Shock (2009).
  87. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management? Curr Opin Support Palliat Care 3, 7-13 (2009).
  88. Navari, R. M. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother 10, 629-644 (2009).
  89. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther (2009).
  90. Furuse, S. et al. Reduction of Bone Cancer Pain by Activation of Spinal Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the Spinal Cord in a Murine Model of Bone Cancer Pain. Anesthesiology (2009).
  91. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of glioblastoma in humans. Brain Res Bull 79, 333-337 (2009).
  92. Udler, M. S. et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer (2009).
  93. Luca, T. et al. The CB(1)/CB(2) receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro. Eur J Pharmacol (2009).
  94. Galal, A. M. et al. Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications. Recent Pat CNS Drug Discov 4, 112-136 (2009).
  95. Liang, C. et al. A Population-Based Case-Control Study of Marijuana Use and Head and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila Pa) (2009).
  96. Surtees, P. G., Wainwright, N. W., Luben, R. N., Khaw, K. T. & Bingham, S. A. No evidence that social stress is associated with breast cancer incidence. Breast Cancer Res Treat (2009).
  97. Biro, T., Toth, B. I., Hasko, G., Paus, R. & Pacher, P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci (2009).
  98. Han, K. H. et al. CB1 and CB2 Cannabinoid Receptors Differentially Regulate the Production of Reactive Oxygen Species by Macrophages. Cardiovasc Res (2009).
  99. Oesch, S. & Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? J Pharm Pharmacol 61, 839-853 (2009).
  100. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A. & Flygare, J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res 7, 1086-1098 (2009).
  101. Ramesh, Shukla, N. K. & Bhatnagar, S. Phantom breast syndrome. Indian J Palliat Care 15, 103-107 (2009).
  102. Surtees, P. G. et al. No association between APOE and major depressive disorder in a community sample of 17,507 adults. J Psychiatr Res (2009).
  103. Dunning, A. M. et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet (2009).
  104. Van Dross, R. T. Metabolism of anandamide by COX-2 is necessary for endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog (2009).
  105. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia (2009).
  106. Pisanti, S. et al. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab 23, 117-131 (2009).
  107. Froger, N. et al. Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments. J Neurochem 111, 1383-1397 (2009).
  108. Madeddu, C. & Mantovani, G. An update on promising agents for the treatment of cancer cachexia. Curr Opin Support Palliat Care (2009).
  109. Mantovani, G. & Madeddu, C. Cancer cachexia: medical management. Support Care Cancer (2009).
  110. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2). Br J Cancer (2009).
  111. Zhao, P., Leonoudakis, D., Abood, M. E. & Beattie, E. Cannabinoid Receptor Activation Reduces TNFalpha-Induced Surface Localization of AMPAR-Type Glutamate Receptors and Excitotoxicity. Neuropharmacology (2009).
  112. Pisanti, S. & Bifulco, M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res 60, 107-116 (2009).
  113. Moayyeri, A. et al. Estimation of absolute fracture risk among middle-aged and older men and women: the EPIC-Norfolk population cohort study. Eur J Epidemiol (2009).
  114. Santoro, A. et al. Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer (2009).
  115. Wang, Q. et al. Pretreatment With Electroacupuncture Induces Rapid Tolerance to Focal Cerebral Ischemia Through Regulation of Endocannabinoid System. Stroke (2009).
  116. Gallant, M., Odei-Addo, F., Frost, C. L. & Levendal, R. A. Biological effects of THC and a lipophilic cannabis extract on normal and insulin resistant 3T3-L1 adipocytes. Phytomedicine (2009).
  117. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest (2009).
  118. El-Talatini, M. R. et al. Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 4, e4579 (2009).
  119. Keeley, P. W. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009, (2009).
  120. Alpini, G. & Demorrow, S. Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer. Vitam Horm 81C, 469-485 (2009).
  121. Bifulco, M., Santoro, A., Laezza, C. & Malfitano, A. M. Chapter 7 Cannabinoid Receptor CB1 Antagonists State of the Art and Challenges. Vitam Horm 81, 159- 189 (2009).
  122. Wang, J. et al. Expression and secretion of N-acylethanolamine-hydrolyzing acid amidase in human prostate cancer cells. J Biochem (2008).
  123. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 30, 271-280 (2008).
  124. Khasabova, I. A. et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 28, 11141-11152 (2008).
  125. Eichele, K., Ramer, R. & Hinz, B. R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway. Pharm Res (2008).
  126. Demorrow, S. et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol 294, G506-19 (2008).
  127. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. Cannabis Smoke Condensate II: Influence of Tobacco on Tetrahydrocannabinol Levels. Inhal Toxicol 1 (2008).
  128. Burstein, S. & Salmonsen, R. Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation. Bioorg Med Chem (2008).
  129. Czifra, G. et al. Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin Oncol (2008).
  130. Lissoni, P. et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. Anticancer Res 28, 3743-3748 (2008).
  131. Giuliano, M. et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: Involvement of the transcription factor PPARgamma. Biochimie (2008).
  132. Purohit, V., Gao, B. & Song, B. J. Molecular Mechanisms of Alcoholic Fatty Liver. Alcohol Clin Exp Res (2008).
  133. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Delta(9)- tetrahydrocannabinol on human breast cancer cells. Oncogene (2008).
  134. Casida, J. E., Nomura, D. K., Vose, S. C. & Fujioka, K. Organophosphate-sensitive lipases modulate brain lysophospholipids, ether lipids and endocannabinoids. Chem Biol Interact (2008).
  135. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42 Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and Cannabinoids. Neurotoxicol Teratol (2008).
  136. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68, 3992-3998 (2008).
  137. Deutsch, S. I. et al. Current Status of Cannabis Treatment of Multiple Sclerosis with an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics, Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol. CNS Spectr 13, 393-403 (2008).
  138. Surtees, P. G. et al. Psychological distress, major depressive disorder, and risk of stroke. Neurology 70, 788-794 (2008).
  139. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin type-8 (TRPM-8). J Pharmacol Exp Ther (2008).
  140. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 68, 1945-1952 (2008).
  141. Endsley, M. P. et al. Expression and Function of Fatty Acid Amide Hydrolase in Prostate Cancer. Int J Cancer (2008).
  142. Iribarne, M. et al. Cannabinoid Receptors in Conjunctival Epithelium: Identification and Functional Properties. Invest Ophthalmol Vis Sci (2008).
  143. Gustafsson, K. et al. Expression of Cannabinoid Receptors Type 1 and Type 2 in Non-hodkin Lymphoma: Growth Inhibition By Receptor Activation. Int J Cancer (2008).
  144. Bifulco, M., Malfitano, A. M., Pisanti, S. & Laezza, C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer 15, 391-408 (2008).
  145. Widmer, M., Hanemann, O. & Zajicek, J. High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. J Neurosci Res (2008).
  146. Habayeb, O. M., Taylor, A. H., Bell, S. C., Taylor, D. J. & Konje, J. C. Expression of the Endocannabinoid System in Human First Trimester Placenta and its Role in Trophoblast Proliferation. Endocrinology (2008).
  147. Machado Rocha, F. C., Stefano, S. C., DE Cassia Haiek, R., Rosa Oliveira, L. M. & DA Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) (2008).
  148. Rahn, E. J. et al. Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. J Pharmacol Exp Ther (2008).
  149. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol (2008).
  150. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol (2008).
  151. von Bueren, A. O., Schlumpf, M. & Lichtensteiger, W. Delta(9)- tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res 28, 85-89 (2008).
  152. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100, 59-69 (2008).
  153. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 68, 339-342 (2008).
  154. Warr, D. G. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol 15, S4-9 (2008).
  155. Jones, J. D., Carney, S. T., Vrana, K. E., Norford, D. C. & Howlett, A. C. Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells. Neuropharmacology 54, 23-30 (2008).
  156. Bari, M. et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology 54, 45-50 (2008).
  157. Blazquez, C. et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology 54, 235-243 (2008).
  158. Notarnicola, M. et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 43, 66-72 (2008).
  159. Shi, Y. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene Ther 15, 101-107 (2008).
  160. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 104, 1091-1100 (2008).
  161. Rudolph, M. I. et al. The Influence of Mast Cell Mediators on Migration of SW756 Cervical Carcinoma Cells. J Pharmacol Sci 106, 208-218 (2008).
  162. Ware1, M. A., Daeninck, P. & Maida, V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 4, 99-107 (2008).
  163. Russo, E. B. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 4, 245-259 (2008).
  164. Diaz, P. et al. 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design, Synthesis, and Binding Mode Prediction. J Med Chem (2008).
  165. Sugamura, K. et al. Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Circulation (2008).
  166. Chung, S. C. et al. A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer (2008).
  167. Cianchi, F. et al. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor {alpha}-Mediated Ceramide De novo Synthesis in Colon Cancer Cells. Clin Cancer Res 14, 7691-7700 (2008).
  168. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB(2) receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008).
  169. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection. Prog Retin Eye Res (2008).
  170. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68, 6468-6476 (2008).
  171. Santoro, A. et al. Reply to the letter to the editor "Long-term cannabinoid receptor (CB1) blockade in obesity: Implications for the development of colorectal cancer". Int J Cancer (2008).
  172. Potenzieri, C., Harding-Rose, C. & Simone, D. A. The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res (2008).
  173. Ernst, G. & Kongsgaard, U. E. [Use of cannabinoids in palliative medicine.]. Tidsskr Nor Laegeforen 128, 822-825 (2008).
  174. DUBOIS. Turned-off Cannabinoid Receptor Turns on Colorectal Tumor Growth. Newswise (2008).
  175. Bilsland, L. G. & Greensmith, L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des 14, 2306-2316 (2008).
  176. Massi, P., Valenti, M., Bolognini, D. & Parolaro, D. Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des 14, 2289-2298 (2008).
  177. Galanti, G. et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 47, 1062-1070 (2008).
  178. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med (2007).
  179. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 19, 704-708 (2007).
  180. Peters, M. & Kogan, N. M. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin Investig Drugs 16, 1405-1413 (2007).
  181. Michalski, C. W. et al. Cannabinoids in pancreatic cancer: Correlation with survival and pain. Int J Cancer (2007).
  182. Holland, M. L., Lau, D. T., Allen, J. D. & Arnold, J. C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol (2007).
  183. Mukhopadhyay, S. & Tulis, D. A. Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem 5, 311-318 (2007).
  184. Gary-Bobo, M. et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (2007).
  185. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical marijuana and the developing role of the pharmacist. Am J Health Syst Pharm 64, 1037-1044 (2007).
  186. Varvel, S. A., Martin, B. R. & Lichtman, A. H. Lack of behavioral sensitization after repeated exposure to THC in mice and comparison to methamphetamine. Psychopharmacology (Berl) (2007).
  187. Slatkin, N. E. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5, 1-9 (2007).
  188. Tham, C. S., Whitaker, J., Luo, L. & Webb, M. Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Lett 581, 2899-2904 (2007).
  189. Taylor, A. H., Ang, C., Bell, S. C. & Konje, J. C. The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum Reprod Update (2007).
  190. Greenhough, A., Patsos, H. A., Williams, A. C. & Paraskeva, C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer (2007).
  191. Gkoumassi, E. et al. Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br J Pharmacol (2007).
  192. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene (2007).
  193. Vila, A., Rosengarth, A., Piomelli, D., Cravatt, B. & Marnett, L. J. Hydrolysis of Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes, Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase. Biochemistry (2007).
  194. Udler, M. et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 25, 3015-3023 (2007).
  195. Schramm-Sapyta, N. L. et al. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology (Berl) S (2007).
  196. Jordan, K., Schmoll, H. J. & Aapro, M. S. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol S (2007).
  197. Aguado, T. et al. Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem S (2007).
  198. Demorrow, S. et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of fas and fas ligand to lipid rafts. J Biol Chem S (2007).
  199. Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S. & Santoro, A. Rimonabant: Just an Anti-obesity Drug? Current Evidence on Its Pleiotropic Effects. Mol Pharmacol (2007).
  200. Darmani, N. A., Janoyan, J. J., Crim, J. & Ramirez, J. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol S (2007).
  201. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social and health aspects. AIDS Care S 19, 295-301 (2007).
  202. Athanasiou, A. et al. Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364, 131-137 (2007).
  203. Takeda, S. et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology (2007).
  204. Flygare, J. & Sander, B. The endocannabinoid system in cancer-Potential therapeutic target? Semin Cancer Biol (2007).
  205. Engels, F. K. et al. Medicinal cannabis in oncology. Eur J Cancer 43, 2638-2644 (2007).
  206. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. Chem Biodivers 4, 1729-1743 (2007).
  207. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid Modulation of Kaposi's Sarcoma Associated Herpesvirus Infection and Transformation. Cancer Res 67, 7230-7237 (2007).
  208. Kempf, K. et al. Immune-mediated Activation of the Endocannabinoid System in Visceral Adipose Tissue in Obesity. Horm Metab Res 39, 596-600 (2007).
  209. Batkai, S. et al. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 293, H909-18 (2007).
  210. Velasco, G. et al. Cannabinoids and gliomas. Mol Neurobiol 36, 60-67 (2007).
  211. De Filippis, D. et al. Local administration of WIN 55,212-2 reduces chronic granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J Mol Med (2007).
  212. Bifulco, M., Laezza, C., Gazzerro, P. & Pentimalli, F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review). Oncol Rep 17, 813-816 (2007).
  213. D'Souza, D. C. Cannabinoids and psychosis. Int Rev Neurobiol S 78, 289-326 (2007).
  214. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14, 917-936 (2007).
  215. Sunil K. Aggarwal, M. S. I. I. I., PhC, BS, BA, Muraco Kyashna-Tocha, PhD; Gregory T. Carter, MD, MS. Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. (2007).
  216. Kingsley, P. J. & Marnett, L. J. LC-MS-MS Analysis of Neutral Eicosanoids. Methods Enzymol 433, 91-112 (2007).
  217. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. Dialogues Clin Neurosci 9, 413-430 (2007).
  218. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. J Org Chem 71, 7800-7804 (2006).
  219. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58, 389-462 (2006).
  220. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6, 677-684 (2006).
  221. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58, 714-725 (2006).
  222. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318, 1375- 1387 (2006).
  223. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem (2006).
  224. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J (2006).
  225. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18, 1584-1594 (2006).
  226. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99, 677-688 (2006).
  227. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171, 31-38 (2006).
  228. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori, V. Participation of the Endocannabinoid System in the Effect of TNF-{alpha} on Hypothalamic Release of Gonadotropin-Releasing Hormone. Ann N Y Acad Sci S 1088, 238-250 (2006).
  229. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol (2006).
  230. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND - INDEPENDENT IMMUNOMODULATORY EFFECTS. J Biol Chem 281, 14192- 14206 (2006).
  231. Alsasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. Cell Mol Neurobiol (2006).
  232. Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148, 123-135 (2006).
  233. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Mol Pharmacol (2006).
  234. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett 580, 1733-1739 (2006).
  235. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6, 257-268 (2006).
  236. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. Pediatr Res (2006).
  237. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer (2006).
  238. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid Rafts Mediated Mechanism. Mol Pharmacol (2006).
  239. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24, 3394- 3400 (2006).
  240. Carracedo, A. et al. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes. Cancer Res 66, 6748-6755 (2006).
  241. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Delta}9- Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. Cancer Res 66, 6615-6621 (2006).
  242. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55, 946-953 (2006).
  243. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530, 54-58 (2006).
  244. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm Res 23, 90-94 (2006).
  245. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J Leukoc Biol 79, 202-213 (2006).
  246. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 49, 1113-1117 (2006).
  247. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312, 363-373 (2006).
  248. Vignot, S. et al. [Cannabis and cancer]. Bull Cancer 93, 163-170 (2006).
  249. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283, 75-83 (2006).
  250. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor- evoked hyperalgesia. Eur J Pharmacol S (2006).
  251. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. J Cell Physiol S (2006).
  252. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. & Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res S (2006).
  253. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. Anal Biochem SO - Anal Biochem. 2006 Dec 20;d (2006).
  254. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer (2006).
  255. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest 116, 2122-2131 (2006).
  256. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. Mol Cancer Res 4, 549-562 (2006).
  257. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R. Cannabinoid receptors in human astroglial tumors. J Neurochem 98, 886-893 (2006).
  258. Perez, J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42, 495-503 (2006).
  259. Matias, I. et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91, 3171-3180 (2006).
  260. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105, 1-25 (2006).
  261. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramide- dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res (2006).
  262. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 71, 1146-1154 (2006).
  263. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).
  264. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6, 656-665 (2006).
  265. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: current status. Methods Find Exp Clin Pharmacol 28, 177-183 (2006).
  266. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66, 234-246 (2006).
  267. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. Cas Lek Cesk 145, 453-7; discussion 458-9 (2006).
  268. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 12, 3135-3146 (2006).
  269. Huskey, A. Cannabinoids in cancer pain management. J Pain Palliat Care Pharmacother 20, 43-46 (2006).
  270. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. Interjournal Complex Systems 1669 (2006).
  271. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N- arachidonoyldopamine. J Immunol 175, 3990-3999 (2005).
  272. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct J 2, 21 (2005).
  273. Sun, Y. X. et al. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736, 211-220 (2005).
  274. Kogan, N. M. Cannabinoids and cancer. Mini Rev Med Chem 5, 941-952 (2005).
  275. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579, 6343-6349 (2005).
  276. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5, 400-411 (2005).
  277. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174, 3281-3289 (2005).
  278. Tashkin, D. P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 63, 93-100 (2005).
  279. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 81, 275- 283 (2005).
  280. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332, 1028-1033 (2005).
  281. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206, 471-478 (2005).
  282. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219 (2005).
  283. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down- regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17, 25-37 (2005).
  284. Chung, K. F. Drugs to suppress cough. Expert Opin Investig Drugs 14, 19-27 (2005).
  285. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6, 35-42 (2005).
  286. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913 (2005).
  287. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105, 1214-1221 (2005).
  288. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs 10, 151-171 (2005).
  289. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6, 93-102 (2005).
  290. Roila, F. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 13, 129-131 (2005).
  291. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem (Tokyo) 137, 217-223 (2005).
  292. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579, 6885-6889 (2005).
  293. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res 28, 1365-1375 (2005).
  294. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33, 712-714 (2005).
  295. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19, 1338-1340 (2005).
  296. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29, 915-922 (2005).
  297. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74, 31-40 (2005).
  298. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. J BUON 10, 181-188 (2005).
  299. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280, 12212-12220 (2005).
  300. Fride, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230, 225-234 (2005).
  301. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144, 1032-1036 (2005).
  302. Guzman, M. Effects on cell viability. Handb Exp Pharmacol 627-642 (2005).
  303. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. Handb Exp
  304. Pharmacol 573-598 (2005).
  305. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies,
  306. and clinical trials. AAPS J 7, E143-8 (2005).
  307. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol
  308. (Delta 9-THC) on humans. Toxicon 44, 461-467 (2004).
  309. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P. G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med 2, 34 (2004).
  310. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol 63, 956-963 (2004).
  311. Juttler, E. et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor- kappa B (NF-kappa B). Neuropharmacology 47, 580-592 (2004).
  312. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47, 315-323 (2004).
  313. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special emphasis on aged patients]. Nippon Ronen Igakkai Zasshi 41, 460-467 (2004).
  314. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18, 1606-1608 (2004).
  315. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamide- induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun 324, 621-626 (2004).
  316. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. Schmerz (2004).
  317. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am 15, 943-54, ix (2004).
  318. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol 492, 1-11 (2004).
  319. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis: rational guidelines for dosing. IDrugs 7, 464-470 (2004).
  320. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309, 745-757 (2004).
  321. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis and endocannabinoid system]. Med Clin (Barc) 122, 390-398 (2004).
  322. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64, 1943-1950 (2004).
  323. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308, 838-845 (2004).
  324. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 380, 435-440 (2004).
  325. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz 18, 203-210 (2004).
  326. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. Schmerz 18, 197-202 (2004).
  327. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2, 305-14; discussion 314-6 (2004).
  328. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47, 3800-3806 (2004).
  329. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. Rev Neurol (Paris) 160, 639-649 (2004).
  330. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120, 138-144 (2004).
  331. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. Gastroenterol Clin Biol 28, 97 (2004).
  332. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262 (2004).
  333. Sancho, R. et al. Immunosuppressive activity of endovanilloids: N-arachidonoyl- dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol 172, 2341-2351 (2004).
  334. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 147, 127-130 (2004).
  335. Fowler, C. J. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol Sci 25, 59-61 (2004).
  336. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord 3, 507-514 (2004).
  337. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4, 572-579 (2004).
  338. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64, 5617-5623 (2004).
  339. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53, 723-728 (2004).
  340. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863 (2004).
  341. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93, 182-188 (2004).
  342. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor- dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278, 33896-33903 (2003).
  343. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced activation of ERK and AKT in mast cells may be mediated by intracellular NO production. J Immunol 171, 2767 (2003).
  344. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1- arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol 66, 757-767 (2003).
  345. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15, 851-859 (2003).
  346. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17, 1771-1773 (2003).
  347. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687 (2003).
  348. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140, 115-122 (2003).
  349. Klein, T. W. et al. The cannabinoid system and immune modulation. J Leukoc Biol 74, 486-496 (2003).
  350. Guzman, M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, 745-755 (2003).
  351. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 17, 2157-2159 (2003).
  352. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64, 1189-1198 (2003).
  353. Wrobleski, S. T. et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46, 2110-2116 (2003).
  354. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170, 4953-4962 (2003).
  355. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103, 175-186 (2003).
  356. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti Prog Med 94, 194-198 (2003).
  357. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. N- Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem 11, 817-825 (2003).
  358. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104, 12-18 (2003).
  359. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal Biochem 314, 8-15 (2003).
  360. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17, 529-531 (2003).
  361. New toke on treating skin cancer. Lab Anim (NY) 32, 12 (2003).
  362. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102, 211-216 (2003).
  363. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166, 156-162 (2003).
  364. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137-143 (2003).
  365. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary? Support Care Cancer 11, 133-134 (2003).
  366. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46, 2352-2360 (2003).
  367. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139, 775-786 (2003).
  368. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12, 39-44 (2003).
  369. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161-168 (2003).
  370. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458, 207-215 (2003).
  371. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111, 43-50 (2003).
  372. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65, 649-655 (2003).
  373. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of Thc on Human Lung Epithelial Cells. Toxicol Appl Pharmacol (2008).
  374. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278, 48973-48980 (2003).
  375. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555, 561-566 (2003).
  376. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 64, 1334-1341 (2003).
  377. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. Expert Opin Pharmacother 4, 2367-2371 (2003).
  378. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res 980, 197-205 (2003).
  379. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 42, 9041-9049 (2003).
  380. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6- hydroxydopamine-lesioned rats. Pharmacol Toxicol 93, 66-70 (2003).
  381. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. Schmerz 17, 274-279 (2003).
  382. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100, 4269-4274 (2003).
  383. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol 77, 201-207 (2003).
  384. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. Adv Exp Med Biol 525, 145- 152 (2003).
  385. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42, 327-360 (2003).
  386. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202 (2003).
  387. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9, 1607-1633 (2003).
  388. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs R D 4, 306-309 (2003).
  389. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells. Leuk Lymphoma 44, 1767-1773 (2003).
  390. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277, 36527- 36533 (2002).
  391. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-44885 (2002).
  392. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck cancer. J Clin Pharmacol 42, 103S-107S (2002).
  393. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101, 93-102 (2002).
  394. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132, 1012-1017 (2002).
  395. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52, 72-91 (2002).
  396. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs 3, 437-440 (2002).
  397. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF- alpha production by human mononuclear cells. Int Immunopharmacol 2, 537-543 (2002).
  398. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3, 859-864 (2002).
  399. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8, 547-550 (2002).
  400. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett 133, 171-179 (2002).
  401. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).
  402. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66, 319-332 (2002).
  403. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66, 257-267 (2002).
  404. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66, 211-220 (2002).
  405. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66, 101-121 (2002).
  406. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J Biol Chem 277, 50348-50354 (2002).
  407. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62, 1385-1392 (2002).
  408. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J 366, 137-144 (2002).
  409. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2- arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45, 3709-3720 (2002).
  410. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. FEBS Lett 525, 164- 168 (2002).
  411. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62, 4398-4405 (2002).
  412. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16, 297-302 (2002).
  413. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport 13, 593-596 (2002).
  414. Jorda, M. A. et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786-2793 (2002).
  415. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo- synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363, 183-188 (2002).
  416. Zurcher, G. [Anorectic syndrome]. Z Gastroenterol 40 Suppl 1, S71-S5 (2002).
  417. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an
  418. update. Adv Exp Med Biol 507, 381-386 (2002).
  419. Kalant, H. Medicinal use of cannabis: history and current status. Pain Res Manag 6,
  420. 80-91 (2001).
  421. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. Pain Res
  422. Manag 6, 74-79 (2001).
  423. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6, 67-73 (2001).
  424. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 286, 1144-1152 (2001).
  425. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic non- psychoactive cannabinoid. Biochem Pharmacol 62, 755-763 (2001).
  426. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9- tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25, 565-571 (2001).
  427. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134, 1151-1154 (2001).
  428. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24, 339-344 (2001).
  429. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 7, 43-61 (2001).
  430. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86, 2687-2696 (2001).
  431. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol Pharmacol 59, 1369-1375 (2001).
  432. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).
  433. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase. Biochemistry 40, 861-866 (2001).Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76, 594-601 (2001).
  434. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)- Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268, 531-535 (2001).
  435. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198-203 (2001).
  436. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogene- dependent tumor growth. FASEB J 15, 2745-2747 (2001).
  437. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299, 951-959 (2001).
  438. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur J Pharmacol 425, 73-83 (2001).
  439. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358, 249-255 (2001).
  440. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J Neurosci Res 65, 346-353 (2001).
  441. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid 2-arachidonylglycerol. J Biol Chem 276, 30072-30077 (2001).
  442. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61, 5784-5789 (2001).
  443. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)- tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol Appl Pharmacol 174, 264-272 (2001).
  444. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem 78, 835-841 (2001).
  445. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133, 1263-1275 (2001).
  446. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol 132, 1743-1754 (2001).
  447. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur J Biochem 268, 1982-1989 (2001).
  448. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61, 955-977 (2001).
  449. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death decision by cannabinoids. J Mol Med 78, 613-625 (2001).
  450. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme immunoassays for the sensitive detection of fentanyl. Forensic Sci Int 113, 353-357 (2000).
  451. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug development. Curr Pharm Des 6, 1361-1380 (2000).
  452. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406, R5-7 (2000).
  453. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275, 31938-31945 (2000).
  454. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225, 1-8 (2000).
  455. Carriot, F. & Sasco, A. J. [Cannabis and cancer]. Rev Epidemiol Sante Publique 48, 473-483 (2000).
  456. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2- arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun 278, 576-583 (2000).
  457. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 108, 191-209 (2000).
  458. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology 141, 1675-1685 (2000).
  459. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur J Biochem 267, 2991-2997 (2000).
  460. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates. Anticancer Res 20, 861-867 (2000).
  461. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6, 313-319 (2000).
  462. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165, 373-380 (2000).
  463. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPS- inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (2000).
  464. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141, 118-126 (2000).
  465. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated T- cells and activator protein-1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292, 597-605 (2000).
  466. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serum- dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60, 1807-1813 (2000).
  467. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39, 1331-1336 (2000).
  468. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347, 369-373 (2000).
  469. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharm Res 23, 121-127 (2000).
  470. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.]. Bull Cancer 87, 299-300 (2000).
  471. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J Pharmacol Exp Ther 293, 289-295 (2000).
  472. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti- inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293, 136- 150 (2000).
  473. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 61, 43-61 (2000).
  474. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and cannabinoids]. An R Acad Nac Med (Madr) 117, 595-605; discussion 616-24 (2000).
  475. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. FEBS Lett 458, 400-404 (1999).
  476. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim Biophys Acta 1440, 266-274 (1999).
  477. Gorter, R. W. Cancer cachexia and cannabinoids. Forsch Komplementarmed 6 Suppl 3, 21-22 (1999).
  478. Mechoulam, R. Recent advantages in cannabinoid research. Forsch Komplementarmed 6 Suppl 3, 16-20 (1999).
  479. Studies of high-dose chemotherapy with stem cell support for breast cancer. Am J Health Syst Pharm 56, 940 (1999).
  480. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. J Virol 73, 3595-3602 (1999).
  481. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C. Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: structural requirements determined by peptide analysis. Biochemistry 38, 3447-3455 (1999).
  482. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids. Am J Respir Cell Mol Biol 20, 1286-1293 (1999).
  483. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N- arachidonoylphosphatidylethanolamine in SK-N-SH cells. J Neurochem 72, 522- 528 (1999).
  484. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262, 275-284 (1999).
  485. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. Am J Obstet Gynecol 181, 491-497 (1999).
  486. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9- tetrahydrocannabinol and its metabolites on the immune system]. Acta Clin Belg Suppl 1, 39-43 (1999).
  487. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469, 527-533 (1999).
  488. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9- tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436, 6-10 (1998).
  489. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett 436, 449-454 (1998).
  490. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. J Biol Chem 273, 32332-32339 (1998).
  491. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179-185 (1998).
  492. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6, 204-214 (1998).
  493. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells--implications for cell proliferation and differentiation. Eur J Biochem 254, 634-642 (1998).
  494. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 21, 353-356 (1998).
  495. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management in advanced cancer. Psychooncology 7, 346-358 (1998).
  496. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 95, 8375-8380 (1998).
  497. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248, 515-522 (1998).
  498. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41, 163-170 (1998).
  499. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425, 419-425 (1998).
  500. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331, 15-19 (1998).
  501. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. Life Sci 63, PL197-204 (1998).
  502. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol Res 4, 191-199 (1998).
  503. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 239, 473-479 (1997).
  504. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 8, 1929-1933 (1997).
  505. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9- tetrahydrocannabinol and marijuana. Ann Intern Med 126, 791-798 (1997).
  506. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the immunocompromised. Altern Ther Health Med 3, 39-45 (1997).
  507. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322, 671-677 (1997).
  508. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells. Biochem Pharmacol 53, 207-214 (1997).
  509. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 53, 35-41 (1997).
  510. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231, 217-221 (1997).
  511. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142, 278-287 (1997).
  512. Sanchez, C., Velasco, G. & Guzman, M. Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Res 767, 64-71 (1997).
  513. Axelrod, R. S. Antiemetic therapy. Compr Ther 23, 539-545 (1997).
  514. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced
  515. nausea and vomiting. Oncol Nurs Forum 24, 20-32 (1997).
  516. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci 60, 1563-1573 (1997).
  517. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-
  518. arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res Commun 227, 281-288 (1996).Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human neuroblastoma cell line. Gen Pharmacol 27, 1141-1143 (1996).
  519. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser S 446, 1-317 (1996).
  520. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol. Pharmacology 52, 271-282 (1996).
  521. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 30, 109-117 (1996).
  522. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 316, 977-984 (1996).
  523. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 212, 123-126 (1996).
  524. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor necrosis factor alpha maturation and secretion but not its transcription in mouse macrophages. Int J Immunopharmacol 18, 53-68 (1996).
  525. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 39, 197-221 (1996).
  526. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15, 6552- 6561 (1995).
  527. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proc Soc Exp Biol Med 210, 64-76 (1995).
  528. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N- 18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). Biochem Pharmacol 49, 855-858 (1995).
  529. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9- Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 209, 205-212 (1995).
  530. Fride, E. et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 272, 699-707 (1995).
  531. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. Pharmacol Biochem Behav 50, 141-146 (1995).
  532. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express cannabinoid receptors? Biochem Soc Trans 23, 418S (1995).
  533. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano- Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56, 2065-2072 (1995).
  534. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9- tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10, 14-18 (1994).
  535. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 269, 22937-22940 (1994).
  536. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of tumor necrosis factor by human large granular lymphocytes. Cell Immunol 154, 99- 108 (1994).
  537. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein expression in mouse peritoneal macrophages. Biochem Pharmacol 47, 2243-2252 (1994).
  538. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. Int J Immunopharmacol 16, 593-603 (1994).
  539. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer patients. Cancer Surv 21, 99-115 (1994).
  540. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54, 1831-1844 (1994).
  541. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9- Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sci 54, 1281-1289 (1994).
  542. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 365, 61-65 (1993).
  543. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol 44, 498-503 (1993).
  544. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267, 635-640 (1993).
  545. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44, 1008-1015 (1993).
  546. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? Support Care Cancer 1, 298-304 (1993).
  547. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214, 173-180 (1993).
  548. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9- tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post- translational events. J Pharmacol Exp Ther 267, 1558-1565 (1993).
  549. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A. delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15, 371- 382 (1993).
  550. Tchekmedyian, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr 16, 88S-92S (1992).
  551. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9- tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 14, 1445-1452 (1992).
  552. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89, 3825-3829 (1992).
  553. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). Drugs 43, 295-315 (1992).
  554. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106, 231-232 (1992).
  555. Bruera, E. Current pharmacological management of anorexia in cancer patients. Oncology (Huntingt) 6, 125-30; discussion 132, 137 (1992).
  556. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic therapy. Clin Pharmacokinet 23, 147-160 (1992).
  557. Nahas, G. & Latour, C. The human toxicity of marijuana. Med J Aust 156, 495-497 (1992).
  558. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 49 Suppl 2, 35-42 (1992).
  559. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9- tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in neuroblastoma cells. Brain Res 560, 245-250 (1991).
  560. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of natural killer but not natural cytotoxic activity in a cloned cell line by delta-9- tetrahydrocannabinol. J Leukoc Biol 50, 192-197 (1991).
  561. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 288, 63-70 (1991).
  562. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. Int J Immunopharmacol 13, 1091-1097 (1991).
  563. Tashkin, D. P. Pulmonary complications of smoked substance abuse. West J Med 152, 525-530 (1990).
  564. Johnson, B. A. Psychopharmacological effects of cannabis. Br J Hosp Med 43, 114- 6, 118-20, 122 (1990).
  565. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol 68, 304-313 (1990).
  566. Tortorice, P. V. & O'Connell, M. B. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy 10, 129-145 (1990).
  567. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem Pharmacol 38, 3297-3304 (1989).
  568. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 249, 444-449 (1989).
  569. Grunberg, S. M. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Rev 3, 216-221 (1989).
  570. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs 6, 243-246 (1988).
  571. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 244, 1157-1163 (1988).
  572. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2- induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol 10, 485-488 (1988).
  573. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs 34, 136-149 (1987).
  574. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC carbamate. Alcohol Drug Res 7, 517-523 (1987).
  575. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic analogs having psychoactivity. NIDA Res Monogr 79, 148-157 (1987).
  576. Roffman, R. A. Stress inoculation training in the control of THC toxicities. Int J Addict 21, 883-896 (1986).
  577. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol 8, 741- 745 (1986).
  578. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 10, 143-166 (1985).
  579. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9- tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 69, 109-112 (1985).
  580. Perlin, E. et al. Disposition and bioavailability of various formulations of tetrahydrocannabinol in the rhesus monkey. J Pharm Sci 74, 171-174 (1985).
  581. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient-- the UCLA study. Part II: Patient drug preference. Am J Clin Oncol 8, 142-147 (1985).
  582. Bakowski, M. T. Advances in anti-emetic therapy. Cancer Treat Rev 11, 237-256 (1984).
  583. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol. Chemical synthesis and biological testing and evaluation as a potentially site- specific anti-tumor agent. Sci Sin [B] 27, 1048-1058 (1984).
  584. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic drug- induced vomiting]. Klin Wochenschr 62, 441-445 (1984).
  585. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and behavioral management of chemotherapy-induced emesis. Arch Intern Med 144, 1029-1033 (1984)Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and vomiting. Cancer 54, 2642-2648 (1984).
  586. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9- tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68, 1427-1431 (1984).
  587. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in patients with testicular cancer. Lancet 2(8359), 1144 (1983).
  588. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic research legislation for cancer patients. JAMA 249, 1469-1472 (1983).
  589. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99, 106-114 (1983).
  590. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs 25 Suppl 1, 1-7 (1983).
  591. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use]. Fortschr Med 100, 343-346 (1982).
  592. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer Institute program in Wisconsin. Wis Med J 81, 24 (1982).
  593. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9 Suppl B, 3-9 (1982).
  594. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 50, 636-645 (1982).
  595. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother Pharmacol 9, 61-64 (1982).
  596. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC dispensing. Pharm Times 47, 32-36 (1981).
  597. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9- tetrahydrocannabinol in clinical oncology. JAMA 245, 2047-2051 (1981).
  598. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic. Am J Hosp Pharm 38, 639-646 (1981).
  599. Procedure for obtaining THC for cancer patients. JAMA 246, 15-19 (1981).
  600. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9- Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. J Clin Pharmacol 21, 70S-75S (1981).Garb, S. Cannabinoids in the management of severe nausea and vomiting from cancer chemotherapy. Some additional considerations. J Clin Pharmacol 21, 57S- 59S (1981).
  601. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21, 214S-223S (1981).
  602. Dow, G. J. & Meyers, F. H. The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy. J Clin Pharmacol 21, 128S-132S (1981).
  603. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of delta 9-tetrahydrocannabinol (NSC-134454). J Clin Pharmacol 21, 122S-127S (1981).
  604. Scigliano, J. A. THC therapeutic research by independent and state-sponsored investigators: a historical review. J Clin Pharmacol 21, 113S-121S (1981).
  605. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 21, 11S-22S (1981).
  606. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 21, 103S- 109S (1981).
  607. Gunby, P. Many cancer patients receiving THC as antiemetic. JAMA 245, 1515, 1518 (1981).
  608. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47, 1746-1751 (1981).
  609. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients? Opinion 2. CA Cancer J Clin 30, 283-285 (1980)
  610. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. CA Cancer J Clin 30, 278-282 (1980).
  611. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and vomiting in cancer patients. J Med Assoc Ga 69, 919-920 (1980).
  612. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. JAMA 243, 1241-1243 (1980).
  613. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9- tetrahydrocannabinol and prochlorperazine. N Engl J Med 302, 135-138 (1980).
  614. Levy, J. A. & Heppner, G. H. Immunosuppression by marihuana and its cannabinoid constituents. J Immunopharmacol 2, 159-177 (1980).
  615. Ekert, H., Waters, K. D., Jurk, I. H., Mobilia, J. & Loughnan, P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9- tetrahydrocannabinol. Med J Aust 2, 657-659 (1979).
  616. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91, 825-830 (1979).
  617. Chang, A. E. et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 91, 819-824 (1979).
  618. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis. Naturwissenschaften 65, 174-179 (1978).
  619. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of cortiocosteroidogenesis by delta-9-tetrahydrocannabinol. Endocrinology 101, 1815-1820 (1977).
  620. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas. Cancer Biochem Biophys 2, 51-54 (1977).
  621. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta9- tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl Cancer Inst 56, 655-658 (1976).
  622. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis by cannabinoids. Cancer Res 36, 95-100 (1976).
  623. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55, 597-602 (1975).
  624. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18, 84-89 (1975).
  625. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9- tetrahydrocannabinol. J Clin Pharmacol 15, 139-143 (1975).